Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Mar 28 02:04PM ET
2.57
Dollar change
+0.03
Percentage change
1.22
%
Index- P/E- EPS (ttm)-0.22 Insider Own5.45% Shs Outstand89.24M Perf Week-3.71%
Market Cap230.17M Forward P/E- EPS next Y-0.29 Insider Trans0.00% Shs Float84.65M Perf Month0.04%
Income-18.75M PEG- EPS next Q-0.11 Inst Own13.60% Short Float2.21% Perf Quarter45.25%
Sales33.46M P/S6.88 EPS this Y100.00% Inst Trans-29.75% Short Ratio2.54 Perf Half Y176.44%
Book/sh0.73 P/B3.50 EPS next Y- ROA-17.40% Short Interest1.87M Perf Year256.43%
Cash/sh0.57 P/C4.51 EPS next 5Y- ROE-26.19% 52W Range0.53 - 3.03 Perf YTD29.84%
Dividend Est.- P/FCF- EPS past 5Y12.14% ROI-28.30% 52W High-15.15% Beta2.63
Dividend TTM- Quick Ratio4.36 Sales past 5Y94.22% Gross Margin94.01% 52W Low385.08% ATR (14)0.17
Dividend Ex-Date- Current Ratio4.36 EPS Y/Y TTM44.54% Oper. Margin-38.83% RSI (14)50.39 Volatility4.93% 7.19%
Employees68 Debt/Eq0.02 Sales Y/Y TTM346.12% Profit Margin-56.05% Recom1.00 Target Price5.33
Option/ShortYes / Yes LT Debt/Eq0.01 EPS Q/Q407.84% Payout- Rel Volume0.41 Prev Close2.54
Sales Surprise67.30% EPS Surprise6.49% Sales Q/Q346.12% EarningsMar 05 BMO Avg Volume738.07K Price2.57
SMA20-3.87% SMA506.32% SMA20083.26% Trades Volume219,534 Change1.22%
Date Action Analyst Rating Change Price Target Change
Aug-05-22Downgrade Jefferies Buy → Hold $2
May-26-20Resumed JMP Securities Mkt Outperform $18
May-13-20Initiated Stifel Buy $19
May-07-20Initiated SVB Leerink Outperform
Apr-22-20Initiated ROTH Capital Buy $28
Mar-24-20Initiated SunTrust Buy $16
Jan-16-20Initiated Cantor Fitzgerald Overweight $10
Mar-29-18Initiated Oppenheimer Outperform
Feb-01-16Resumed Oppenheimer Outperform
Oct-15-15Initiated FBR Capital Outperform $14
Mar-12-24 12:00PM
Mar-11-24 07:00AM
Mar-07-24 09:41AM
Mar-06-24 07:00AM
Mar-05-24 11:53AM
07:16AM Loading…
07:16AM
07:00AM
Feb-29-24 08:58AM
Feb-26-24 07:00AM
Feb-21-24 12:00PM
Feb-20-24 07:00AM
Feb-15-24 07:00AM
Jan-08-24 07:05AM
07:00AM
Dec-19-23 10:11AM
07:10AM Loading…
07:10AM
07:05AM
07:00AM
Dec-15-23 08:17AM
Dec-05-23 09:40AM
Nov-08-23 04:41PM
Nov-07-23 07:28AM
07:00AM
Nov-06-23 07:00AM
Nov-03-23 04:35PM
Oct-31-23 09:00AM
Oct-24-23 07:00AM
Oct-03-23 07:00AM
Oct-02-23 07:00AM
Sep-27-23 09:00AM
09:40AM Loading…
Sep-14-23 09:40AM
Aug-31-23 07:00AM
Aug-29-23 09:40AM
Aug-10-23 12:13PM
Aug-07-23 07:17AM
07:00AM
Jul-24-23 07:00AM
Jul-17-23 07:00AM
Jun-22-23 07:00AM
Jun-13-23 07:00AM
Jun-05-23 07:00AM
Jun-02-23 07:09AM
May-25-23 10:49AM
May-18-23 09:40AM
May-15-23 07:10AM
07:00AM
May-11-23 07:00AM
May-09-23 07:00AM
May-01-23 07:00AM
Apr-27-23 07:00AM
Apr-26-23 07:00AM
Mar-15-23 07:00AM
Mar-14-23 09:40AM
Mar-13-23 06:30AM
Mar-10-23 02:08AM
Mar-08-23 07:00AM
Mar-06-23 07:00AM
Feb-28-23 12:17PM
Feb-27-23 07:00AM
Feb-14-23 07:00AM
Feb-13-23 07:00AM
Feb-09-23 07:00AM
Feb-08-23 05:25PM
Jan-27-23 09:32AM
Jan-23-23 07:00AM
Dec-29-22 04:53PM
Dec-06-22 07:00AM
Dec-01-22 07:00AM
Nov-30-22 04:49PM
Nov-29-22 07:00AM
Nov-17-22 04:51PM
Nov-16-22 07:00AM
Nov-14-22 06:52PM
07:00AM
Nov-08-22 07:00AM
Nov-07-22 08:00AM
08:00AM
Nov-02-22 07:00AM
Nov-01-22 04:41PM
Oct-31-22 07:00AM
Oct-26-22 07:00AM
Oct-06-22 07:00AM
Sep-22-22 07:00AM
Sep-12-22 07:00AM
Sep-07-22 07:00AM
Sep-01-22 02:32PM
Aug-24-22 07:00AM
Aug-08-22 07:00AM
Aug-04-22 07:00AM
Jul-29-22 12:29PM
Jul-21-22 07:00AM
Jul-03-22 10:28AM
Jun-27-22 07:00AM
Jun-01-22 07:00AM
May-16-22 07:00AM
May-13-22 09:27AM
May-10-22 07:00AM
May-02-22 07:00AM
Apr-13-22 02:55PM
Mar-30-22 02:41PM
Compugen Ltd. engages in the research, development, and commercialization of therapeutic and diagnostic biomarker product candidates including proteins and monoclonal antibodies. It focuses on research and development on immuno-oncology and autoimmune diseases. The company was founded by Eli Mintz, Simchon Faigler, and Amir Natan on February 10, 1993 and is headquartered in Holon, Israel.